Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to...Show More

Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to meet Nasdaq's listing standards. Stockholders of record as of July 26, 2024, are eligible to vote at the meeting. The Board recommends voting in favor of the reverse stock split. The meeting will also address any other business that may properly come before it. Voting can be done electronically during the meeting or by proxy via telephone, internet, or mail as detailed in the Proxy Statement.